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ABSTRACT 
About 97% of synovial sarcomas harbor the SYT-SSX fusion gene by chromosomal 
translocation. We found that the histone deacetylase (HDAC) inhibitor FK228 
significantly suppressed the growth of synovial sarcoma cells as compared with that of 
osteosarcoma. The 50% growth inhibition IC50 value we obtained for FK228 was 
0.02-0.2 nM, and  it indicates that its suppression effect on synovial sarcoma cells is the 
highest of any of the HDAC inhibitors yet reported. It was not likely that the growth 
suppression of FK228 depends on the doubling time of these cells. Introduction of 
SYT-SSX cDNA into HEK293 cells enhanced the sensitivity of the cells for FK228. 
Immunostaining of the FK228-treated cells using an anti-acetyl-histone H3 antibody 
showed that FK228 inhibits deacetylation of histone. In a mice assay, the growth of 
synovial sarcoma cells was markedly inhibited by FK228 treatment, and the invasion of 
tumors into surrounding tissues was suppressed. These results suggest that FK228 may be 
useful in developing therapeutic strategies to treat synovial sarcoma. 
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1. Introduction 
Synovial sarcomas are soft tissue tumors, occurring at any age but affecting mainly young 
adults. They are considered high-grade sarcomas because they lead to death in at least 
25% of patients within the first five years following diagnosis, despite advances in 
treatment [1]. These sarcomas are characterized cytogenetically by the presence of a 
chromosomal translocation t(X;18)(p11.2;q11.2), where the SYT gene on chromosome 18 
is translocated to one of the closely related SSX family genes on chromosome X [2]. The 
SYT protein is associated with a chromatin remodeling factor hBRM/hSNF2 alpha 
protein [3], a transcriptional coactivator p300 protein [4], and a transcriptional factor 
AF10 [5]. Functional studies have shown that the acidic C-terminus of SSX carries a 
repressor domain [3, 6, 7]. SSX proteins have been reported to show colocalization with 
several members of the Polycomb group proteins which are associated with 
transcriptional repression [7]. Splicing isoform of the SYT-SSX fusion protein was 
reported to accelerate the transcriptional activity and cell proliferation [8]. 
     Recently, we found that SYT proteins interact with mSin3A, a component of histone 
deacetylase (HDAC) complex, and reported that HDAC activity may be associated with 
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the tumorigenesis of synovial sarcomas [9]. In the present study, by using an 
HDAC-specific inhibitor FK228 (depsipeptide or FR901228) which was isolated from a 
culture broth of Chromobacterium violaceum [10, 11] and has been reported to be 
effective for treating malignant T-cell lymphomas [12], we examined the effect of HDAC 
inhibitor on synovial sarcoma cells with the chromosomal translocation 
t(X;18)(p11·2;q11·2). We found that the histone deacetylase inhibitor FK228 
significantly suppressed the growth of synovial sarcoma cells as compared with that of 
osteosarcoma. 
 
2. Materials and methods  
2.1. Materials  
Histone deacetylase inhibitor FK228 was provided by the Fujisawa Pharmaceutical Co. 
(Osaka, Japan). FK228 was dissolved in 0.1% ethanol for in vitro experiments, and 
dissolved in 10% polyoxyethylene-hydrogenated castor oil (Wako Pure Chemical 
Industries, Osaka, Japan) and diluted with 0.9% NaCl solution for in vivo experiments.   
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2.2. Cell lines 
Synovial sarcoma cell lines HS-SY-2, YaFuSS and SYO-1 were provided by Dr. H. 
Sonobe (National Fukuyama Hospital, Hiroshima, Japan), Dr. J. Toguchida (Institute for 
Frontier Medical Sciences, Kyoto University, Japan) and Dr. A. Kawai (National Cancer 
Center, Tokyo, Japan), respectively. Osteosarcoma cell line, Saos2, and human normal 
embryonic kidney cell line, HEK293, were purchased from American Type Culture 
Collection.   
 
2.3. Reverse transcriptase-polymerase chain reaction (RT-PCR) 
Total RNA was extracted from cells using Isogen reagent (Nippon Gene, Tokyo, Japan) 
according to the manufacturer’s instructions. Synthesis of cDNA was performed using 
ReverTra Ace (Toyobo, Tokyo, Japan). Identification of SYT-SSX cDNA was performed 
by PCR with SYT forward primer 5’-CAA CAG CAA GAT GCA TAC CA and SSX1 
reverse primer 5’-ACA CTC CCT TCG AAT CAT TTT CG or SSX2 reverse primer 
5’-GCA CTT CCT CCG AAT CAT TTC as described in a previous paper [13]. The 
amplified products were confirmed by DNA sequencing with an ABI3100 sequencer 
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(Applied Biosystems, Foster City, CA, USA). 
 
2.4. Tumor growth assay in vitro 
All cell lines were split into 96-well plates (103 cells/well), and cultured with 0.001-100 
nM of histone deacetylase inhibitor FK228. After exposure to FK228 for 24, 48 and 72 
hrs, cell viability was determined in four individual experiments by MTT assay kit 
(Chemicon International Inc., Temecula, CA) according to the Manufacturer’s 
instructions. IC50 was determined by nonlinear regression analysis applying the 
inhibition data to the dose-response curve. 
 
2.5. Transfection 
Human embryonic kidney 293 cells were transfected with pCMV-SYT-SSX1 and 
pCMV-SYT-SSX2, which contain the cDNAs amplified by RT-PCR [9], by Effectene 
reagent (Qiagen, Hilden, Germany), and selected with 400 µg /ml of G418 (Sigma, St. 
Louis, MO, USA) for 2 weeks. 
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2.6. Tumor growth assay in vivo 
Animals were treated according to the animal experimental guidelines of Okayama 
University. Twenty male mice (BALB/c nu/nu) were inoculated subcutaneously with 
SYO-1 synovial sarcoma cells (105 cells/mouse). Injection of FK228 (50 μl) into the 
veins of the 20 mice was started 10 days after subcutaneous inoculation of SYO-1 cells, 
and performed 3 times every 4 days. Body weight was measured every 4 days. Tumor 
volume was measured every 4 days for two right-angled diameters with slide calipers, 
and was calculated using the following formula: tumor volume  = 1/6π[(d1×d2)3/2]  
(where d1 and d2 are the two perpendicular diameters)[14]. Using another set of the 
inoculated 20 mice, tumors were resected at day 20 after subcutaneous inoculation of 
SYO-1 cells, and tumor weight was measured after the invaded internal organs were 
removed from them as well as possible.  
The relationship between the tumor weight and FK228-treatment was statistically 
analyzed by Student’s t-test. 
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2.7. Histopathology 
Tumors were fixed overnight in 10% (v/v) formaldehyde/0.9% NaCl solution before 
paraffin embedding and routine sectioning. Three representative hematoxylin-eosin 
stained sections were examined for each tumor. Specimens on slides were incubated with 
anti-histone H3 (1:200) (Cell Signaling Technology, Beverly, MA, USA) or 
anti-acetylated histone H3 antibody (1:200) (Cell Signaling Technology) for 1 hr at room 
temperature. Immunoreactive signals were visualized by FITC-labeled rabbit IgG or by 
using diaminobenzidine. 
 
3. RESULTS 
We confirmed the expression of fusion genes in synovial sarcoma cell lines by RT-PCR. 
HS-SY-2 and YaFuSS expressed the SYT-SSX1 gene, and SYO-1 expressed the SYT-SSX2 
gene (Figure 1, lanes 1-3), suggesting that these cell lines are derived from synovial 
sarcomas. As a control, Saos2 osteosarcoma cell line was used and shown no SYT-SSX 
fusion genes (Figure 1, lanes 4). Next, we examined the effect of FK228 on the growth of 
these cells. Most notably, a significant growth inhibition was observed in the synovial 
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sarcoma cells as compared with that of Saos2 (Figures. 2A-D and 3). The concentration 
of FK228 at 50% growth inhibition (IC50) was 0.2 nM in HS-SY-2, 0.02 nM in YaFuSS 
and 0.03 nM in SYO-1 at 48 hr after treatment (Table 1), while osteosarcoma cell line, 
Saos2, showed 9.33 nM of IC50. Doubling time of these cells was measured, but it is not 
likely that the growth suppression of FK228 depends on the doubling time (Table 1). 
SYO-1 cells carrying the SYT-SSX2 gene showed more sensitive growth inhibition to 
FK288 at least at 24 hr than HS-SY-2 and YaFuSS both of which have the SYT-SSX1 gene. 
To examine whether the SYT-SSX fusion proteins affect on the growth suppression by 
FK228, the SYT-SSX cDNA expression vectors were transfected into HEK293 cells. 
G418-resistant clones were gathered, and the SYT-SSX gene expression was confirmed by 
RT-PCR (Figure 1, lanes 5-7). These transformants expressing SYT-SSX gene showed an 
enhanced sensitivity to FK228 when compared to that of the cells bearing empty vector 
(Figure 2E). Growth of HEK293 cells carrying the SYT-SSX2 gene was suppressed at 
lower concentration of FK228 than that of the SYT-SSX1 transformants was. 
Immunostaining of the FK228-treated SYO-1 cells using an anti-acetyl-histone H3 
antibody showed the nuclear localization of the acetylated histone, suggesting that FK228 
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inhibits deacetylation of histone (Figure 4). 
     The SYO-1 cell line was used to examine the tumor suppression effect of FK228 on 
synovial sarcoma cells in vivo, because the cell line is known to grow well in mice 
xenografts. Mice treated with FK228 (1.6 and 3.2 mg/kg mouse) showed significantly 
reduced growth of SYO-1 cells when compared to those treated with the vehicle (Figures 
5A and 6A). The tumors resected from FK228-treated mice exhibited significantly weight 
loss more than those from mice treated with the vehicle (Figure 5B). Intra-abdominal 
invasion of the tumor tissues was observed in most mice in the vehicle-treated group, and 
the internal organs of the back/peritoneal region, including the spine and kidney, were 
involved in the tumors (Figure 6B). However, intra-abdominal invasion was not observed 
in any of the FK228-treated mice (Figure 6C). HE staining of tumors revealed that the 
tumors of the vehicle-treated group were of a high density, while those of the 
FK228-treated group were of a comparatively low density (Figure 6D-F). Epithelioid-like 
spindle cells and round cells were observed in vehicle-treated group, while spindle cells 
were absent in the tumors from the FK228-treated group. In the tumors from 
FK228-treated group, infiltration of lymphocytes was frequently detected, and a high rate 
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of necrosis was observed (data not shown). Immunohistochemical studies using 
anti-acetylated histone antibody showed the presence of acetylated histone in tumor 
tissues of the FK228-treated group (Figure 6H), suggesting that this drug inhibits 
deacetylation of histone in tumors of FK228-treated mice. The body weight of the mice 
treated with FK228 showed a transient decrease upon treatment with the drug (Figure 5C), 
suggesting that it might produce some side effects. 
 
4. Discussion 
Recently, we reported that SYT proteins interact with mSin3A, a component of HDAC 
complex [9], which suggests that HDAC activity may be associated with the 
tumorigenesis and malignancy of synovial sarcoma. Therefore, by using HDAC inhibitor 
FK228, we examined the effect of the HDAC inhibitor on growth of synovial sarcoma. 
Interestingly, a significant growth inhibition was observed in the synovial sarcoma cells 
as compared with that of Saos2. A recent study on acute myelogenous leukemias revealed 
that the AML1-ETO fusion protein disrupts normal hematopoiesis by blocking 
trans-activation of AML1 target genes through recruitment of HDAC1 by ETO [15], in 
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addition to reports on the anti-tumor effects of HDAC inhibitors on various cancer cells 
[16]. The LC50 (50% cytotoxicity) of FK228 for the acute myelogeneous leukemia cells 
was 4.6 nM at 48 hrs [17], while the IC50 value of FK228 in our results was 0.02-0.2 nM 
in synovial sarcoma cells at 48 hrs after treatment. This is the lowest concentration yet 
reported for any of the known HDAC inhibitors. Our results of SYT-SSX 
cDNA-transfection experiment suggest that SYT-SSX fusion protein may associate with 
the growth suppression by FK228. The relation between the SYT protein and histone 
acetylation/deacetylation has been also implied in studies of histone acetyltransferase 
p300 [4] and mSin3A [9]. Our results showed that the cells carrying the SYT-SSX2 gene 
are more sensitive to FK228 than the cells carrying the SYT-SSX1 gene. It has been 
reported that the type of the SYT-SSX fusion gene influences the clinical outcome [18, 19], 
and the phenomenon we found may be associated with the mechanism by which the 
clinical outcome is affected. But further studies with lots of cell lines will be required to 
clarify the unsolved issues. High viability of SYO-1 cells treated with FK228 at a 
concentration of 0.001 nM was reproducibly observed (Figure 2C). SYO-1 cells may be 
still affected by low concentration (0.001 nM) of FK228, but may be able to overcome the 
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stress by cellular defense system like degradation or export of the reagent at lower 
concentration, leading to the stimulation of the cell growth by unknown mechanism. The 
IC50 of osteosarcoma cell line, Saos2, was reported to be 2.6 nM at 72 hr [20], and it was 
9.33 nM at 48 hr in our results. There is a tendency that the sensitivity of Saos2 for FK228 
in our experiment is lower than that of their report, but it might be caused by different 
subtypes of culture cells. 
     In the FK228-treated mice, synovial sarcoma cells were significantly reduced in size 
and did not show invasion into other organs, while weight reduction was transiently 
observed in mice treated with a high concentration of FK228. A phase1 study with FK228 
showed that dose-limited toxicity caused fatigue, nausea, vomiting, and transient 
thrombocytopenia and neutropenia [21]. Moreover, reversible electrocardiogram (ECG) 
changes with ST/T wave flattening were regularly observed in 37 malignant tumor 
patients [21]. Although FK228 is currently expected to be used as an universal 
anti-neoplastic agent , it may be necessary to use the drug in low concentrations to avoid 
producing some of the side effects mentioned here. 
     SYT-SSX fusion gene has been detected in nearly 97% cases of synovial sarcomas [22]. 
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At present, the 5-year overall survival rates for synovial sarcomas are 53% for the 
SYT-SSX1 type and 73% for the SYT-SSX2 type [23]. Our findings suggest that FK228 
may be useful in developing therapeutic strategies to treat this form of sarcoma. 
Identification of molecule targets of FK228 and clinical trials of FK228 are necessary to 
find an effective cure for malignant synovial sarcomas, and to gain insight into the 
mechanisms of tumorigenesis in synovial sarcomas.  
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Figure legends 
Figure 1 
Detection of the SYT-SSX transcripts in cell lines. SYT-SSX1 (331 bp) and SYT-SSX2 (331 
bp) cDNAs were detected by RT-PCR. M, DNA molecular weight marker; lane 1, SYO-1; 
lane 2, YaFuSS; lane 3, HS-SY-2; lane 4, Saos2; lane 5, HEK293 transfected with an 
empty vector; lane 6, HEK293 transfected with SYT-SSX1 cDNA expression vector; lane 
7, HEK293 transfected with SYT-SSX2 cDNA expression vecter.  
 
Figure 2 
Effect of FK228 on the growth of cell lines. HS-SY-2 (A), YaFuSS (B), SYO-1 (C) and 
Saos2 (D) were measured using MTT assay at 24, 48 and 72 hr after addition of FK228 
(0.001-100 nM). HEK293 cells bearing cDNA expression vector (E) were measured at 48 
hr after addition of FK228. Viability was calculated by dividing the value of 
FK228-treated cells by the value of the cells treated with the vehicle (0.1% ethanol). Data 
are represented as the mean + s.d. of four individual experiments.  
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Figure 3 
Effect of FK228 on the growth of cell lines. YaFuSS and Saos2 were cultured for 48 hr 
after addition of FK228 (0 - 100 nM) and observed with magnification of X100. 
 
Figure 4 
Inhibition of histone deacetylase by FK228. Immunostaining of SYO-1 cells is shown 
using acetyl-histone H3 antibody (A, C and E) and histone H3 antibody (B, D and F) after 
vehicle-treatment (A and B) and FK228-treatment of 0.1 nM (C and D) and 1 nM (E and 
F) for 3 hrs. Immunoreactive signals were visualized by FITC-labeled rabbit IgG. 
 
Figure 5 
Suppression of SYO-1 cells in mice by FK228. Injection of FK228 into the veins of 20 
mice was started 10 days after subcutaneous inoculation of SYO-1 cells (105 cells/mouse), 
and performed 3 times every 4 days as shown by arrows. Tumor volume (A) and body 
weight (C) were measured every 4 days. Using another set of the inoculated 20 mice, 
tumor weight was measured by resecting at day 20 after subcutaneous inoculation of 
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SYO-1 cells (B). Vehicle, vehicle-treated mice; 1.6 mg/kg, FK228 (1.6 mg/kg)-treated 
mice; 3.2 mg/kg, FK228 (3.2 mg/kg)-treated mice; 3.2 mg/kg w/o tumor, FK228 (3.2 
mg/kg)-treated mice without subcutaneous inoculation of SYO-1 cells. P-value is shown 
against vehicle-treated tumor weight. Data are represented as the mean + s.d.  
  
Figure 6 
Characterization of SYO-1 cells suppressed by FK228. (A) Mice treated with the vehicle 
(left) and with  a concentration of 1.6 mg/kg of FK228 (center) and with a concentration 
of 3.2 mg/kg of FK228 (right). (B and C) Tumor cells in the mice treated with the vehicle 
(B) and 3.2 mg/kg of FK228 (C). (D-F) Hematoxylin-eosin staining of tumor tissues. (D) 
Tumor tissue treated with the vehicle. This tumor was composed of spindle and round 
cells with different cell sizes and atypical nuclei. (E and F) Tumor tissues treated with 
FK228 at a concentration of 1.6 mg/kg and 3.2 mg/kg, respectively. The living cells were 
mostly round cells, with few spindle cells remaining. (G-J) Immunohistochemical studies 
of acetylated histone H3. Tumors in mice treated with the vehicle (G and I) and a 
concentration of 3.2 mg/kg of FK228 (H and J) were immunostained with anti 
acetyl-histone H3 (G and H) and anti-histone H3 antibody (I and J)  at day 22 after 
inoculation of SYO-1 cells into another set of mice.  Immunoreactive signals were 
visualized with diaminobenzidine. 
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Figure 6 
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Table 1  
IC50 of FK228 and doubling time of sarcoma cells 
Cells  Fusion gene IC501 Doubling time (hr) 
HS-SY2  SYT-SSX1 0.20 25.0 
YaFuSS  SYT-SSX1 0.02 24.9 
SYO-1  SYT-SSX2 0.03 18.6 
Saos2  none  9.33 17.9 
1 IC50; 50% growth inhibition value (nM) at 48 hr after FK228 addition 
